[{"id":"fae174c0-98ea-47ef-93cf-33fa869c7950","acronym":"","url":"https://clinicaltrials.gov/study/NCT05390710","created_at":"2022-05-25T12:57:02.573Z","updated_at":"2024-07-02T16:35:21.609Z","phase":"Phase 1","brief_title":"PhI to Solid Tumors and PhII to Locally Advanced or mTNBC","source_id_and_acronym":"NCT05390710","lead_sponsor":"Laekna Limited","biomarkers":" HER-2 • PD-L1 • ER • PGR • PTEN • BRCA • PI3K","pipe":" | ","alterations":" PD-L1 expression • PGR expression","tags":["HER-2 • PD-L1 • ER • PGR • PTEN • BRCA • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • afuresertib (LAE002) • LAE005"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 06/12/2021","start_date":" 06/12/2021","primary_txt":" Primary completion: 12/11/2023","primary_completion_date":" 12/11/2023","study_txt":" Completion: 12/11/2023","study_completion_date":" 12/11/2023","last_update_posted":"2024-01-31"}]